EXELIXIS, INC.
EXEL · Healthcare · $14.6B mkt cap · FY2025 filings · Wide moat
On the watchlist
The four filters
Pricing power100
Median gross margin 96.4% over 10y, very stable.
Returns on capital76
Median ROIC 17.7%, above the 9% hurdle in 60% of years.
Balance-sheet safety100
Net cash position — no leverage risk.
Capital discipline63
Owner earnings trend unclear, share count shrinking (buybacks).
Margin of safety
Above valueOn sale
- Owner earnings (normalized)
- $231.1M
- Est. intrinsic value / share
- $15.85
- Recent price
- $55.79
- Discount to value
- 252% above value
Conservative model: 9% discount rate, 4% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).
Moat Score history
Score history begins 2026-07-17. Check back as the record builds.
Scores are logged append-only and never overwritten — this record can't be backfilled, which is exactly why it's worth keeping.